Clinical Trial Details
| Trial ID: | L2866 |
| Source ID: | NCT02605772 |
| Associated Drug: | Acarbose |
| Title: | Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: Acarbose|DRUG: Metformin|DRUG: Saxagliptin |
| Outcome Measures: | Primary: redunction of Hemoglobin A1c (HbA1c) Levels (%) in two groups respectively after three months intervention, HbA1c was measured by high performance liquid chromatography with an automated biochemistry analyzer (Roche, Switzerland)., baseline(0 week), week twelve | Secondary: Proportion of patients who achieve target of HbA1c<6.5% in two groups respectively at the end of study, baseline(0 week), week twelve|Difference of Homeostasis model assessment of insulin resistance (HOMA-IR) and Homeostasis model assessment beta cell function index (HOMA-β) between two groups after three months intervention, HOMA-β= Fasting C-Peptide × 0.27/(Fasting Plasma Glucose-3.5 HOMA-IR = 1.5 + Fasting Plasma Glucose × Fasting CPeptide/ 2800., baseline(0 week), week twelve |
| Sponsor/Collaborators: | Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 100 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2015-12 |
| Completion Date: | 2017-03 |
| Results First Posted: | |
| Last Update Posted: | 2015-11-18 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT02605772 |
